Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary sclerosing cholangitis.

Jayant A Talwalkar1, Keith D Lindor

  • 1Division of Gastroenterology & Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA. talwalkar.jayant@mayo.edu

Inflammatory Bowel Diseases
|January 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Betaine in the treatment of steatotic liver disease-Historical fad or a timeless treasure worth reviving?

Hepatology (Baltimore, Md.)·2025
Same author

Serum miRNA profiles are altered in patients with primary sclerosing cholangitis receiving high-dose ursodeoxycholic acid.

JHEP reports : innovation in hepatology·2023
Same author

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival.

Liver international : official journal of the International Association for the Study of the Liver·2023
Same author

Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis.

Hepatology (Baltimore, Md.)·2023
Same author

Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis.

The American journal of gastroenterology·2023
Same author

Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe.

European journal of gastroenterology & hepatology·2022
Same journal

Patients with Crohn's disease achieving transmural healing experience superior long-term outcomes compared with those with endoscopic or radiologic healing alone.

Inflammatory bowel diseases·2026
Same journal

Higher body mass index is associated with lower drug concentrations in patients with inflammatory bowel disease treated with ustekinumab but not vedolizumab.

Inflammatory bowel diseases·2026
Same journal

Association of preoperative neoplasia and rectal cuff inflammation on initial pouchoscopy with subsequent neoplasia development in inflammatory bowel disease patients with an ileal pouch-anal anastomosis: a case-control study.

Inflammatory bowel diseases·2026
Same journal

Pediatric bowel-wall thickness cutoffs: calibration before implementation.

Inflammatory bowel diseases·2026
Same journal

Trained immunity: Breaking a dogma and a missing opportunity in IBD?

Inflammatory bowel diseases·2026
Same journal

Response to the letter to the editor: "pediatric bowel-wall thickness cutoffs: calibration before implementation".

Inflammatory bowel diseases·2026
See all related articles

Primary sclerosing cholangitis (PSC) is a chronic liver disease causing bile duct inflammation and fibrosis, often linked with inflammatory bowel disease (IBD). Currently, no cure exists, making liver transplantation the only option for advanced cases.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Immunology

Background:

  • Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease.
  • It involves inflammation and fibrosis of intra- and extrahepatic bile ducts.
  • PSC frequently coexists with inflammatory bowel disease (IBD), affecting up to 80% of patients in North America and Europe.

Purpose of the Study:

  • To summarize the current understanding of Primary Sclerosing Cholangitis.
  • To highlight the challenges in treating PSC due to poorly understood pathophysiology.
  • To emphasize the significant complications and current treatment limitations.

Main Methods:

  • Literature review of existing studies on PSC.
  • Analysis of epidemiological data regarding PSC and IBD co-occurrence.

Related Experiment Videos

  • Review of current therapeutic strategies and outcomes for PSC.

    • Main Results:

    • PSC is characterized by bile duct inflammation and fibrosis.
    • A strong association exists between PSC and IBD.
    • Effective medical therapies to halt PSC progression are lacking.
    • Complications include metabolic bone disease, colorectal neoplasia, and cholangiocarcinoma.

    Conclusions:

    • The pathophysiology of PSC requires further investigation.
    • There is an unmet need for effective medical treatments for PSC.
    • Liver transplantation is the primary treatment for advanced PSC.
    • Consider PSC diagnosis in IBD patients with abnormal liver tests.